K. Brooks Low, PhD
Professor (Adjunct) of Research, Department of Therapeutic Radiology
|
brooks.low@yale.edu Phone: 203.785.2976 Appt Phone: Fax: 203.785.6309 Yale University School of Medicine Department of Therapeutic Radiology Radiobiology Room HRT 213B P.O. Box 208040 New Haven, Connecticut 06520-8040 |
Degrees/Education:
B.A., Amherst College (1958)
Ph.D., University of Pennsylvania (1965)
Fellowship, New York University Medical Center
Faculty Appointments:
Assistant Professor, Yale University School of Medicine, Department of Therapeutic Radiology (1968-73)
Associate Professor, Yale University School of Medicine, Department of Therapeutic Radiology (1973-78)
Senior Research Scientist, Yale University School of Medicine, Department of Therapeutic Radiology (1978-84)
Professor Adjunct, Yale University School of Medicine, Department of Therapeutic Radiology (1984-Present)
Certifications/Honors:
Fellow, American Academy of Microbiology (2004)
Research Interests:
Project I: how do DNA molecules recombine in vivo? How does DNA damage stimulate recombination and how is recombination related to the repair of damage? Projects in my laboratory are intended to help answer these questions. We are using E. coli and its plasmids and bacteriophages to analyze th e following aspects: 1) What is the mechanism of the long-distance damage-stimulated recombination process which we recently discovered?; 2) How do mutations in various recombination (rec) genes affect recombination frequencies and repair capacities?; 3) Which recombination pathways and gene functions are involved in mismatch repair and mutation, and how does this depend on the particular mismatches present? In all of these projects we are currently using primarily E. coli lac recombination systems.
Project II:
How can bacteria be used to diagnose and treat cancer? Together with colleagues David Bermudes and John Pawelek, we have found that after the introduction of certain Salmonella strains into the bloodstream of tumor-bearing mice, the bacteria go to and multiply preferentially in the tumors. Moreover, the bacteria greatly retard the growth of the tumors, and spread from tumor to tumor. We are currently developing new strains, which will be both safe and efficient to use in this way, as well as combinations of this and other therapies, which will enhance their effectiveness.
I wish to be contacted by interested students (medical, graduate or undergraduates) as a potential research mentor/thesis advisor.
